Health
FDA approves Roivant's oral therapy Lisraya for rare autoimmune disease
The FDA has approved brepocitinib for dermatomyositis, offering a new oral treatment option for patients with the rare condition.
The short version
- The FDA approved brepocitinib, brand-named Lisraya, as a once-daily oral treatment for dermatomyositis.
- Dermatomyositis is a rare autoimmune disease causing muscle weakness and skin rashes, affecting an estimated 40,000 to 70,000 people in the U.S.
- Developed by Roivant and subsidiary Priovant, the pill offers an alternative to standard treatments relying on high-dose steroids and immunosuppressants.
Key facts
- The FDA approved Roivant and Priovant's brepocitinib (brand name Lisraya) for dermatomyositis.[STAT]
- Lisraya is a once-daily oral pill.[STAT]
- Dermatomyositis is a rare autoimmune disease characterized by painful skin rashes and muscle weakness.[STAT]
- According to Roivant, dermatomyositis affects between 40,000 and 70,000 people in the United States.[STAT]
- Standard care for dermatomyositis currently relies on high-dose steroids and immune-suppressing therapies.[STAT]